Comparative Pharmacology
Head-to-head clinical analysis: ANTHIM versus FASENRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTHIM versus FASENRA.
ANTHIM vs FASENRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody, Anti-Interleukin-5 Receptor